Oncopeptides AB (publ) (STO: ONCO)

Market Cap	320.20M
Revenue (ttm)	27.07M
Net Income (ttm)	-282.39M
Shares Out	215.19M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	501,930
Open	1.448
Previous Close	1.450
Day's Range	1.426 - 1.478
52-Week Range	1.426 - 9.400
Beta	-0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 57
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ONCO

Financial Performance

In 2023, Oncopeptides AB's revenue was 35.22 million, an increase of 321.54% compared to the previous year's 8.36 million. Losses were -249.11 million, -26.29% less than in 2022.